Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration

被引：0
作者：
Meidong Zhu
Wijeyanthy Wijeyakumar
Adil R. Syed
Nichole Joachim
Thomas Hong
Geoffrey K. Broadhead
Haitao Li
Kehui Luo
Andrew Chang
机构：
[1] Sydney Retina Clinic & Day Surgery,Save Sight Institute
[2] Sydney Institute of Vision Science,Department of Statistics, Faculty of Science and Engineering
[3] The University of Sydney,undefined
[4] Macquarie University,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2017年 / 255卷
关键词：
Vision-related quality of life (VR-QoL); Neovascular age-related macular degeneration (nAMD); Intravitreal aflibercept; Anti-vascular endothelial growth factor (anti-VEGF); Treatment resistant; Prospective clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：475 / 484
页数：9
相关论文
共 50 条
[41]   Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study [J].
Wachtlin, Joachim ;
Eter, Nicole ;
Hasanbasic, Zoran ;
Keramas, Georgios ;
Rech, Christine ;
Sachs, Helmut ;
Schilling, Harald ;
Wiedemann, Peter ;
Framme, Carsten .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (03) :601-611
[42]   Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab [J].
Hamid, Mohamed A. ;
Abdelfattah, Nizar S. ;
Salamzadeh, Jamshid ;
Abdelaziz, Sahar T. A. ;
Sabry, Ahmed M. ;
Mourad, Khaled M. ;
Shehab, Azza A. ;
Kuppermann, Baruch D. .
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2021, 7 (01)
[43]   Long-Term Results of Pro Re data Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration [J].
Muftuoglu, Ilkay Kilic ;
Arcinue, Cheryl A. ;
Tsai, Frank F. ;
Alam, Mostafa ;
Gaber, Raouf ;
Camacho, Natalia ;
You, Qisheng ;
Freeman, William R. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 167 :1-9
[44]   Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration [J].
Zinkernagel, Martin Sebastian ;
Wolf, Sebastian ;
Ebneter, Andreas .
OPHTHALMOLOGICA, 2016, 235 (01) :42-48
[45]   Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept [J].
Tyagi, Pallavi ;
Juma, Zain ;
Hor, Yong Keen ;
Scott, Neil W. ;
Ionean, Andreea ;
Santiago, Cynthia .
BMC OPHTHALMOLOGY, 2018, 18
[46]   CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT [J].
Mantel, Irmela ;
Gianniou, Christina ;
Dirani, Ali .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (01) :53-58
[47]   The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography [J].
Aghdam, Kaveh Abri ;
Seidensticker, Florian ;
Pielen, Amelie ;
Framme, Carsten ;
Junker, Bernd .
LASERS IN SURGERY AND MEDICINE, 2016, 48 (07) :668-677
[48]   One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration [J].
Arcinue, Cheryl A. ;
Ma, Feiyan ;
Barteselli, Giulio ;
Sharpsten, Lucie ;
Gomez, Maria Laura ;
Freeman, William R. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (03) :426-436
[49]   A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration [J].
Dae Hyun Park ;
Hae Jung Sun ;
Sung Jin Lee .
International Ophthalmology, 2017, 37 :1205-1214
[50]   Course of Neovascular Age-related Macular Degeneration that Showed Limited Response to Both Ranibizumab and Aflibercept [J].
Yun, Jeong Seop ;
Kim, Chul Gu ;
Kim, Jong Woo ;
Kim, Jae Hui .
JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2023, 64 (04) :313-322
12345